# A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

> **NCT02563106** · PHASE2 · COMPLETED · sponsor: **Theriva Biologics, Inc.** · enrollment: 413 (actual)

## Conditions studied

- Clostridium Difficile
- Clostridium Infections

## Interventions

- **DRUG:** SYN-004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02563106
- **Lead sponsor:** Theriva Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563106, "A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02563106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*